What SCARLETRED does

SCARLETRED is an Austrian health AI company that develops and operates a Software as a Medical Device (SaMD) platform for standardized mobile skin imaging and objective AI-powered dermatological analysis. The company is headquartered in Vienna with a wholly-owned US subsidiary in Cambridge, Massachusetts, and serves biopharmaceutical companies, cosmetics firms, contract research organizations (CROs), medical device companies, healthcare providers, and insurance companies. Named customers include Novartis, Sanofi, Boehringer Ingelheim, UCB Pharma, Galderma, Almirall, MoonLake, Leo Pharma, L'Oréal, and Henkel. The company holds CE Class Im medical device certification, ISO 13485 QMS certification, ISO 27001 compliance, and is designed to meet EU AI Act, GDPR, HIPAA, ICH-GCP, and 21 CFR Part 11 standards, with a Class IIa conformity assessment currently in progress.

The core product, Scarletred Vision, runs on standard iOS and Android smartphones and combines proprietary patented technology with AI-driven analysis. Its foundation is a patented skin patch that provides real-time calibration of distance, angle, perspective, color, and illumination, enabling reproducible skin imaging across users, devices, and time. Image analysis uses in-house convolutional neural networks, the patented Standard Erythema Value (SEV*) measurement, Haralick texture parameters, and Individual Typology Angle (ITA°) methodology to quantify lesion size, erythema, pigmentation, and surface characteristics across all Fitzpatrick skin types (I-VI). The ARORA AI-Agent adds automated PII detection and blinding plus Fitzpatrick classification, and a Scarletred Telemedicine variant extends the platform with peer-to-peer video consultation. Companion analytics deliver predictive and process automation capabilities for clinical trial endpoints and eCOA/ePRO workflows.

SCARLETRED generates revenue primarily through enterprise SaaS subscriptions, with custom multi-year agreements priced individually based on trial size, patient population, site count, data volume, and required analyses. An add-on companion analytics offering supports automated scoring, treatment group comparisons, erythema course prediction, and customized analytic services co-developed alongside drug development for Phase III readiness. The company sells direct via field sales in Austria and the US, supplements reach through CRO channel partnerships and medical expert collaborations, and distributes a free companion mobile app through the Apple App Store and Google Play. The firm has been funded historically through non-dilutive Austrian and EU grants (cumulative approximately $5.2 million disclosed through 2020) and remains privately held with no disclosed institutional equity rounds.

Name

SCARLETRED

Legal name

SCARLETRED Holding GmbH

Website

https://scarletred.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

SCARLETRED is a Vienna-based health AI company that provides certified Software as a Medical Device for standardized mobile skin imaging and AI-powered objective dermatological analysis, serving biopharma sponsors, CROs, cosmetics firms, and healthcare providers globally.

Ownership category

akta.pro rank

Product category

Medical Imaging Software (Dermatology SaaS)

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermatology & Topical Skin Treatments (HLAIADAE)

Keywords

• Medical imaging software
• Dermatology clinical trials
• AI skin analysis
• Software as medical device
• Standardized skin imaging

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Software as a Service (SaaS) Subscriptions: The primary revenue model is SaaS delivered on a subscription basis, centrally hosted by SCARLETRED. Customers receive access to the Scarletred Vision platform, mobile app, and analysis tools. Pricing is calculated individually based on trial size, patient population, site count, data volume, and required analysis types. The model enables easy up/down scaling, reducing time and cost for subscribers.
2. Companion Analytics Services: Add-on analytical services for clinical trials including automated scoring of erythema grade, comparison of treatment groups, prediction of erythema course, and customized analytic support developed alongside the drug development process for Phase III readiness.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

SCARLETRED develops and sells Scarletred®Vision, a CE Class Im certified Software as a Medical Device (SaMD) platform that captures standardized 2D/3D and dermoscopic skin images on standard iOS and Android smartphones using a proprietary calibration skin patch. The platform delivers AI-powered objective skin analysis, electronic Clinical Outcome Assessment (eCOA), ePRO patient diaries, and Companion Analytics services for dermatology clinical trials and routine care. Customers are biopharmaceutical companies, cosmetics firms, CROs, hospitals, and medical device companies running clinical trials from preclinical through Phase IV.

Differentiator

Problem solved

Functional benefit

Brands

• Scarletred®Vision: CE-certified Class Im medical device for standardized mobile skin imaging and AI-powered analysis
• Scarletred®Telemedicine
• ARORA®
• Scarletred®Skin Patch

Products and services

• Scarletred®Vision Certified Class Im medical device Software as a Medical Device (SaMD) platform that captures standardized 2D/3D and dermoscopic skin images on iOS and Android smartphones and delivers AI-powered objective skin analysis with eCOA/ePRO capabilities for biopharma, CROs, cosmetics, and healthcare customers.
• Scarletred®Telemedicine Telemedicine platform with peer-to-peer video streaming and teleconsultation channels, integrated with the Scarletred®Vision imaging platform, for primary use by healthcare professionals, nurses, and patients.
• ARORA® AI-Agent AI agent within the Scarletred®Vision ecosystem that automatically detects and blinds personally identifiable information (PII) for privacy compliance and performs automated Fitzpatrick I–VI skin type classification for inclusive analysis across all skin tones.
• Companion Analytics Services Add-on analytical services for clinical trials including automated scoring of erythema grade, comparison of treatment groups, prediction of erythema course, and customized analytic support developed alongside the drug development process for Phase III readiness.

Quantifiable outcome

• Enables standardized assessment across 3,000+ skin diseases and safety-related applications
• +3 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

Five partnerships are on record, tiered core and minor.

• MicrosoftcoreStrategic or Co-development Partner · 1 February 2024Microsoft partnered with Almirall in February 2024 to develop an AI-powered drug discovery platform specifically for dermatology. SCARLETRED's technology may be integrated into this ecosystem as Almirall is a key customer partner.
• AlmirallcoreStrategic or Co-development Partner · 1 February 2024Almirall partnered with Microsoft in February 2024 to develop an AI-powered drug discovery platform for dermatology. Almirall is also a key customer of SCARLETRED's skin imaging technology for clinical trials.
• Leading CROscoreChannel Partner/ Reseller/ DistributorSaaS agreements are powered by partnerships with leading CROs who distribute and support the Scarletred platform for clinical trial applications globally.
• Medical ExpertscoreImplementation/ SI/ Consulting PartnerPartnerships with leading medical experts and radio-oncologist Richard Partl, MD at Landeskrankenhaus Graz for clinical validation and scientific publications including SEV* development.
• Landeskrankenhaus GrazminorStrategic or Co-development PartnerClinical collaboration with radio-oncologist Richard Partl, MD at Landeskrankenhaus Graz, Austria. Joint development and validation of the Standard Erythema Value (SEV*) published in '128 Shades of Red' (2017).

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Skin Analytics: UK-based AI dermatology company with the DERM autonomous skin cancer assessment tool, regulated as a medical device and deployed in NHS pathways. Comparable to SCARLETRED as a regulated AI dermatology imaging platform, but focused on melanoma triage in routine care rather than clinical trial endpoints.
• Apollo Medical Imaging Technologies: Australian developer of AI dermatology imaging software (e.g., DermAssist-style workflows) deployed across clinical and research settings. Comparable as a niche AI skin imaging software vendor competing for similar pharma and CRO use cases as SCARLETRED.
• DermTech: US-listed non-invasive skin genomics company serving dermatologists and biopharma with molecular skin analysis (e.g., melanoma rule-out). Comparable to SCARLETRED as a dermatology-focused diagnostic/monitoring vendor selling to biopharma and clinicians, though based on genomics rather than imaging.
• SkinVision: Amsterdam-based smartphone AI dermatology app focused on skin cancer risk assessment and remote skin monitoring. Comparable to SCARLETRED's smartphone-based imaging approach and direct-to-patient skin analysis, though positioned in consumer/insurer channels rather than pharma trials.
• SciBase Holding: Swedish listed MedTech with the Nevisense platform for AI-supported skin barrier analysis at the point of care. Comparable as a niche AI skin-imaging device vendor targeting dermatology and clinical research, though focused on electrical impedance spectroscopy rather than visual imaging.

Regional players

• MoleMap: Australia/NZ-headquartered skin imaging and teledermatology service for melanoma surveillance. Comparable to SCARLETRED in standardized skin imaging plus AI-assisted lesion assessment, but primarily serves the ANZ market through a clinic network rather than global pharma trials.

Broad incumbents

• VisualDx: US clinical decision support platform with the largest dermatology image reference library, used by clinicians and health systems. Comparable as a digital dermatology platform serving providers, but a broader incumbent focused on differential diagnosis rather than standardized trial imaging.
• Barco / Barco Health: Global medical imaging and visualization company with diagnostic display and clinical imaging solutions used in radiology and dermatology workflows. Comparable as a regulated medical device/visualization vendor serving clinical environments, though focused on display hardware and broader imaging rather than AI skin analytics.

Direct peers

• FotoFinder Systems: German-headquartered dermoscopy and total body photography vendor with AI-based skin analytics (Moleanalyzer pro, FotoFinder AI). Competes head-to-head with SCARLETRED in standardized skin imaging for dermatology clinics and clinical trials across Europe and globally.
• Canfield Scientific: Established US-based provider of clinical skin imaging systems (VISIA, IntelliStudio, VECTRA) widely used in dermatology clinical trials and cosmetics research. Directly comparable to SCARLETRED in serving pharma and cosmetics with standardized skin imaging, though Canfield relies on specialized hardware rather than smartphones.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/scarletred
• Facebookfacebook.com/scarletred.holding
• LinkedInlinkedin.com/company/scarletred/mycompany
• Instagraminstagram.com/scarletredvision

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCARLETRED